Esophageal Pre-Cancer Testing Gaining Greater Traction
How three companies are addressing screening challenges with tests that help improve chances of early detection
How three companies are addressing screening challenges with tests that help improve chances of early detection
Experts—including those in genetics and device regulation—say the AvertD assay did not predict risks of abuse ‘any better than chance’
NIH grant awarded to Metabolon is the first phase of what could be a three-year grant, according to a company official
The grants, which include $3 million from the NIH and $1 million from the NSF, will help the company develop point-of-care tests
Publishing peer-reviewed studies to tout the economic benefits of medical devices is fairly commonplace, but rare for a laboratory company
Though not expected to drastically change the program, new component gives device makers another way to strengthen their submissions
The FDA is adding International Organization for Standardization (ISO) guidelines to its “good manufacturing” requirements
Such assays rely more on imaging and computer power than tissue samples to make diagnoses.
Once confined to areas such as pregnancy testing, these assays can now be used to detect STIs and other health issues.
Approval for OTC use of a urine drug test that can be performed by non-CLIA facilities could help expand accessibility, expert says.
Debate is underway on whether current CLIA review of LDTs properly assesses a test’s likelihood to detect diseases.